Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUCONAZOLE

All products: Limited Use (codes 235)

Diflucan-150 · DIN 02141442 · 150mg · capsule

Limited Use — Reason for Use code 235 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Diflucan-150 · DIN 02141442 Manufacturer: Pfizer Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 2019-07-25 · brand DIFLUCAN ONE · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Pfizer canada ulc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17789 · Verify on the e-Formulary ↗ (DIN 02141442)

Source record
DIN 02141442: Diflucan-150 Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id PFI Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $15.6500; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02141442 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17789
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02141442
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Treatment DIFLUCAN (fluconazole) is indicated for the treatment of: 1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the treatment of serious systemic candidal infections, including urinary tract infection, peritonitis, and pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of cryptococcal meningitis in patients with acquired immunodeficiency syndrome (AIDS). Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Prophylaxis DIFLUCAN is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. 1.1 Pediatrics (<18 years of age) Based on the data submitted and reviewed by Health Canada, the safety and efficacy of DIFLUCAN in pediatric patients ha… https://pdf.hres.ca/dpd_pm/00085459.PDF PM date: 2026-07-21 Source product: DIFLUCAN; DIN 02024152; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.